Seidl U, Pinter A, Wilsmann-Theis D, et al. - The absolute Psoriasis Area and Severity Index (PASI) affords a more valuable tool to measure treatment outcome in psoriasis.

• In this multicenter-retrospective chart review, a total of 74 psoriasis patients who received guselkumab (an anti-interleukin-23p19 monoclonal antibody) treatment were included, and mean PASI at baseline was 13.0 (± 6.7).

• Post-12 weeks of therapy, 40 patients could be followed up.

• An absolute PASI ≤5 (55.0% ≤3; 42.5% ≤2) was achieved in 72.5% and a delta PASI reduction of at least 75% was achieved in 57.5% of patients.

• When the absolute PASI was employed as a treatment goal instead of response rate, a high effectiveness of guselkumab was evident in this real-world setting.